BioSig Announces New Evaluation Agreement for its PURE EP System with Cleveland Clinic
June 22 2022 - 8:00AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) a medical technology company advancing electrophysiology
workflow by delivering greater intracardiac signal fidelity through
its proprietary signal processing platform, today announced it has
entered an evaluation agreement for its PURE EP(TM) System with the
Cleveland Clinic.
The evaluation agreement marks the first since BioSig inducted a
new commercialization team. Consistent with The Company’s stated
national rollout strategy, Cleveland Clinic will participate in a
60-day evaluation of BioSig’s PURE EP(TM) System. The Company
recently announced that is has restructured its clinical support
and installation teams to streamline and accelerate the pathway
from product evaluation to adoption.
“We are excited to include Cleveland Clinic as an evaluation
center for the Pure EP System. We look forward to working alongside
their physicians to demonstrate the superior signal quality that
can be achieved on even the most difficult arrhythmias,” commented
Gray Fleming, Chief Commercialization Officer, BioSig Technologies,
Inc.
Cleveland Clinic is a nonprofit multispecialty academic medical
center that integrates clinical and hospital care with research and
education. U.S. News & World Report consistently names
Cleveland Clinic as one of the nation’s best hospitals in its
annual “America’s Best Hospitals” survey. As a leader in arrhythmia
treatment and diagnosis, Cleveland Clinic medical centers include
state-of-the-art electrophysiology laboratories, world-class
physicians and researchers, and the latest cutting-edge
technologies and protocols deployed for the treatment of heart
abnornmalities. To learn more, visit clevelandclinic.org.
To date, over 75 physicians have completed over 2500 patient
cases with the PURE EP(TM) System. The Company is in a national
commercial launch of the PURE EP(TM) System. The technology is in
regular use in some of the country’s leading centers of excellence,
including Mayo Clinic, and Texas Cardiac Arrhythmia Institute at
St. David’s Medical Center.
Clinical data acquired by the PURE EP(TM) System in a
multi-center study at centers of excellence including Texas Cardiac
Arrhythmia Institute at St. David’s Medical Center was
recently published in the Journal of Cardiovascular
Electrophysiology and is available electronically with open access
via the Wiley Online Library. Study results showed 93% consensus
across the blinded reviewers with a 75% overall improvement in
intracardiac signal quality and confidence in interpreting PURE
EP(TM) signals over conventional sources.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company's first product, PURE EP(TM) System, is a novel
signal processing and acquisition platform designed to extract
advanced diagnostic and therapeutic data that enhances physician
workflow and increases throughput. PURE EP(TM) was engineered to
address the limitations of existing EP technologies by empowering
physicians with superior signals and actionable insights.
Forward-looking Statements
This press release contains "forward-looking statements."
Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions, and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control and cannot be predicted or
quantified, and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social, and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC's website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events, or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024